ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.

Eliglustat tartrate (Genz-112638) is a novel, orally administered agent currently in development for the treatment of lysosomal storage disorders, including type 1 Gaucher disease and Fabry disease. This glucosylceramide analogue acts as an inhibitor of glucosylceramide synthase, a Golgi complex enzyme that catalyzes the formation of glucosylceramide from ceramide and UDP-glucose and is the first step in the formation of glucocerebroside-based glycosphingolipids. Pre-clinical pharmacological studies demonstrate that the agent has a high therapeutic index, excellent oral bioavailability and limited toxicity. Phase I studies in healthy volunteers revealed limited toxicity with an excellent pharmacodynamic response, as measured by decreased plasma glucosylceramide concentrations. Phase II studies in patients with type 1 Gaucher disease have demonstrated promising clinical responses, as measured by decreases in spleen size, improvement in hemoglobin concentrations and increased platelet counts. Two randomized phase III trials testing the efficacy and safety of eliglustat tartrate are currently in progress.

[1]  P. Bonate,et al.  Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz‐112638) After Single Doses, Multiple Doses, and Food in Healthy Volunteers , 2011, Journal of clinical pharmacology.

[2]  P. Bonate,et al.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. , 2010, Blood.

[3]  Laurie A. Smith,et al.  Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models , 2010, Nature Medicine.

[4]  R. Scheule,et al.  Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy , 2010, Journal of Inherited Metabolic Disease.

[5]  J. Shayman,et al.  Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice , 2009, Hepatology.

[6]  Daniel Grinberg,et al.  Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. , 2009, Blood cells, molecules & diseases.

[7]  S. Gummuluru,et al.  Glycosphingolipid Composition of Human Immunodeficiency Virus Type 1 (HIV-1) Particles Is a Crucial Determinant for Dendritic Cell-Mediated HIV-1 trans-Infection , 2009, Journal of Virology.

[8]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[9]  J. M. Aerts,et al.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring , 2008, Journal of Inherited Metabolic Disease.

[10]  C. Ficicioglu.  Review of miglustat for clinical management in Gaucher disease type 1 , 2008, Therapeutics and clinical risk management.

[11]  Joel L Sussman,et al.  Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. , 2007, The Journal of biological chemistry.

[12]  J. Shayman,et al.  A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.

[13]  Seng H. Cheng,et al.  Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes , 2007, Diabetes.

[14]  P. Kaplan,et al.  The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. , 2006, Archives of pediatrics & adolescent medicine.

[15]  C. Mignot,et al.  Type 2 Gaucher disease: 15 new cases and review of the literature , 2006, Brain and Development.

[16]  J. Charrow,et al.  Guidance on the use of miglustat for treating patients with type 1 Gaucher disease , 2005, American journal of hematology.

[17]  P. Kaplan,et al.  Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. , 2004, Seminars in hematology.

[18]  N. Radin.  Treatment of Gaucher disease with an enzyme inhibitor , 1996, Glycoconjugate Journal.

[19]  P. Kaplan,et al.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements , 2004, European Journal of Pediatrics.

[20]  D. Witte,et al.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. , 2003, The American journal of pathology.

[21]  N. Radin,et al.  Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? , 2001, European journal of biochemistry.

[22]  P. Kaplan,et al.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.

[23]  R. Brady,et al.  Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. , 2000, Kidney international.

[24]  J. K. Park,et al.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.

[25]  A. Kulkarni,et al.  Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. , 2000, The Journal of clinical investigation.

[26]  A. Abe,et al.  Inhibitors of glucosylceramide synthase. , 2000, Methods in enzymology.

[27]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[28]  A. Abe,et al.  Improved inhibitors of glucosylceramide synthase. , 1992, The Journal of biological chemistry.

[29]  G. Grabowski,et al.  Gaucher disease: gene frequencies and genotype/phenotype correlations. , 1997, Genetic testing.

[30]  B. Ganem,et al.  Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. , 1995, Journal of lipid research.

[31]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[32]  R. Brady,et al.  Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Santarsiero,et al.  Enantioselective Synthesis of α-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon. , 1990 .

[34]  N. Radin,et al.  Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. , 1980, Chemistry and physics of lipids.

[35]  N. Radin,et al.  A possible therapeutic approach to Krabbe's globoid leukodystrophy and the status of cerebroside synthesis in the disorder. , 1972, Research communications in chemical pathology and pharmacology.